Astellas buys Universal Cells, Teva is affected by Celltrion's manufacturing problem, Korea rolls out a digital health initiative.

Vertex has cancelled plans to test an investigational triple combo at several sites in France.

Teva may be decimating its employee ranks and struggling under a mountain of debt, but Warren Buffett apparently likes what he sees.

Mental health experts question whether allowing Johnson & Johnson to market its antipsychotic med Invega Sustenna as a way to prevent arrest is really a…

With an early approval for its new drug Erleada, J&J just got a head start over Pfizer and Astellas in nonmetastatic prostate cancer.

A former chemist at Merck & Co. is facing criminal charges—and a potential sentence of up to 20 years—after allegedly stealing cyanide from a lab.

Some drugmakers reap far more savings from tax reform than others—and some will actually have to pay more. Here's our report card.

One analyst takeaway from Shire’s 2018 outlook: Consensus earnings estimates probably need to come down.